| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
| ln Vitro |
Gypenoside LXXV inhibits proliferation in a dose-dependent manner over a 48-hour period (1.0–100 μM)[1].
Gypenoside LXXV exhibited anti-cancer properties in vitro. The experiments likely involved the evaluation of its inhibitory effects on the proliferation of cancer cells. Common methods such as cell viability assays (e.g., MTT or CCK-8 assay) might have been used to determine the anti-proliferative activity, and apoptosis detection assays (e.g., flow cytometry or TUNEL assay) could have been conducted to assess its ability to induce cancer cell apoptosis. However, specific data including the types of cancer cell lines used and the half-maximal inhibitory concentration (IC50) values were not obtainable without accessing the full text. [1] |
|---|---|
| Enzyme Assay |
An enzyme assay was performed to determine the activity of the novel ginsenoside-transforming β-glucosidase (isolated from ginseng-cultivating soil bacteria) for the production of Gypenoside LXXV. The assay process probably included the following steps: first, the β-glucosidase was prepared and purified. Then, a specific ginsenoside substrate (which could be converted to Gypenoside LXXV) was mixed with the enzyme in a reaction system with controlled conditions (such as a specific pH value, temperature, and reaction time). After the reaction, the product Gypenoside LXXV was detected and quantified using analytical techniques like high-performance liquid chromatography (HPLC) to evaluate the enzyme's transformation efficiency.
[1] |
| Cell Assay |
Cell Viability Assay[1]
Cell Types: Three cancer cell lines (HeLa (cervical cancer cell line), B16 (melanoma cell line), and MDA-MB231 (human breast cancer cell line) Tested Concentrations: 1.0-100 μM Incubation Duration: For 48 hrs (hours) Experimental Results: decreased proliferation in a dose-dependent manner and inhibited almost all cancer cells at 50 μM. |
| References | |
| Additional Infomation |
Ginsenoside LXXV is a saponin found in plants of the genus Panax. Its structure is that of a dammarane-type compound with hydroxyl groups substituted at the 3β, 12β, and 20 pro-S positions. Specifically, the hydroxyl group at position 20 is converted to the corresponding β-D-glucopyranosyl-(1→6)-β-D-glucopyranoside, and a double bond is introduced at positions 24-25. It is a plant metabolite. It is a 12β-hydroxy steroid, β-D-glucoside, disaccharide derivative, ginsenoside, tetracyclic triterpenoid, 3β-hydroxy steroid, and 3β-hydroxy-4,4-dimethyl steroid. It is derived from the hydride of dammarane. Gypenoside LI saponin LXXV has been reported in Gynostemma pentaphyllum, and relevant data are available. Gypenoside LI saponin LXXV is a ginsenoside whose yield can be increased by using a novel ginsenoside-converting β-glucosidase isolated from bacteria in ginseng cultivation soil. This enzymatic conversion provides an effective method for preparing Gypenoside LI saponin LXXV, a compound with potential anticancer applications, and lays the foundation for further research on its biological activity and related mechanisms. [1]
|
| Molecular Formula |
C42H72O13
|
|---|---|
| Molecular Weight |
785.0133
|
| Exact Mass |
784.497
|
| CAS # |
110261-98-8
|
| PubChem CID |
86289140
|
| Appearance |
White to off-white solid
|
| LogP |
3.5
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
13
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
55
|
| Complexity |
1370
|
| Defined Atom Stereocenter Count |
20
|
| SMILES |
CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O)O)O)C
|
| InChi Key |
YIYRCZFIJNGYOG-QINBLQPGSA-N
|
| InChi Code |
InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,55-37-35(51)33(49)31(47)25(54-37)20-52-36-34(50)32(48)30(46)24(19-43)53-36)22-11-16-41(7)29(22)23(44)18-27-39(5)15-13-28(45)38(3,4)26(39)12-17-40(27,41)6/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36+,37-,39-,40+,41+,42-/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[[(2R,3S,4S,5R,6S)-6-[(2S)-2-[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-en-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~127.39 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2739 mL | 6.3693 mL | 12.7387 mL | |
| 5 mM | 0.2548 mL | 1.2739 mL | 2.5477 mL | |
| 10 mM | 0.1274 mL | 0.6369 mL | 1.2739 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
